Servier, an independent international pharmaceutical company, announced that it has joined Embleema’s Blockchain Health Consortium, a decentralized network based on Blockchain technology, as part of the launch of a pilot blockchain project within the Group. Embleema’s Blockchain Health Consortium, which brings together patient associations, life sciences companies and healthcare professionals, offers patients the opportunity to share digital health data in real time to inform clinical research, enabling better patient engagement and monitoring of their data in real life.
As part of the consortium, Servier will contribute to the construction of the Embleema Blockchain decentralized network, hosting a hub on its servers to securely store and share data, and operate the network to guarantee the safety of sensitive data. This pilot project will run for one year and aims to define and evaluate an operational process before considering deployment of the technology on a larger scale.
“A considerable amount of health data is generated every day, including by patients themselves via, for example, connected objects. This data is an invaluable source of knowledge to accelerate the discovery of new therapeutic solutions. In this context, the Blockchain is seen as a key technology in the creation of a more collaborative model between healthcare professionals and patients,” commented Olivier Laureau, President of Servier. “This is why we are excited to contribute, within the Embleema Health Blockchain Consortium, to the construction of this new model which reflects the commitment of the Group to put patient needs at the center of all its activities.”
Robert Chu, CEO of Embleema added: “Embleema’s health blockchain enables patients to own their data, and allows for better accessibility and transparency of real world data to accelerate drug development and ultimately bring more personalized therapies to patients sooner. We are delighted to welcome Servier to our Health Blockchain Consortium, and look forward to our collaboration to improve patient engagement and data sharing.”
The Consortium’s aims align with the objectives outlined by the 21st Century Cures Act, a healthcare bill signed into U.S. law in 2016, which grants the FDA a mandate to accelerate regulatory approval for new treatments that incorporate the perspectives of patients and real world evidence data reporting. This has led life sciences companies to integrate real world evidence (RWE) into clinical studies, which include Electronic Health Records (EHR), patient reported outcomes and connected health sensors.